TOP10 MNC Seeking FIC or BIC Products: COPD

Project ID: BP-20240430-L-EE-83

COPD: A Growing Global Health Concern

Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disorder characterized by persistent airflow limitation and associated respiratory symptoms. Globally, it affects approximately 300 million people and represents the third leading cause of death worldwide. The current standard of care includes bronchodilators and anti-inflammatory medications such as corticosteroids. However, these treatments often fail to fully meet patient needs due to the heterogeneous nature of the disease and the limitations of existing therapies, particularly in preventing COPD exacerbations.

There is a significant unmet clinical need for novel therapies that can address the underlying pathophysiological mechanisms of COPD and improve patient outcomes. Promising developments in drug research include biological agents targeting type-2 inflammation pathways, such as therapies against IL-4, IL-5, and IL-13, which are under investigation for their potential to treat specific COPD phenotypes with elevated eosinophil levels.

One notable advancement is the drug Dupilumab, which has shown potential in reducing COPD exacerbations in clinical trials and is being prioritized for review by the FDA, indicating a possible new era in COPD treatment. Additionally, other pharmaceutical companies are also working on innovative drugs, such as SHR-1905 by Hengrui Pharma, aiming to provide new treatment options for COPD and other chronic airway diseases.

Despite these advancements, challenges remain in terms of drug accessibility and affordability, especially in low- and middle-income countries, where the majority of COPD patients reside. There is also a need for better diagnostic tools and strategies to identify and manage COPD exacerbations effectively. The market size for COPD treatments is substantial, driven by the large patient population and the ongoing search for more effective therapies.

Request from MNC

Molecular Entities: Large Molecules, Small Molecules, RNA, In Vivo Cell Therapy
Current Stage: Preclinical, Phase I Clinical
Interest in Rights: Global Rights
Collaboration Model: License

How to Contact

If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line.